濟川藥業(600566.SH):曹飛要約收購期滿 股票停牌
格隆匯7月17日丨濟川藥業(600566.SH)公佈,公司於2025年6月16日披露了《湖北濟川藥業股份有限公司要約收購報告書》,曹飛先生向除曹龍祥先生、江蘇濟川控股集團有限公司及西藏濟川企業管理有限公司以外的濟川藥業全體持有無限售條件流通股的股東發出全面要約。本次要約收購股份數量爲350,841,357股,佔公司總股本的38.06%,要約收購價格爲24.85元/股(鑑於公司2024年年度利潤分配方案已實施完畢,本次要約收購的要約收購價格由26.93元/股調整爲24.85元/股),要約收購期限爲2025年6月18日至2025年7月17日。
截至2025年7月17日,本次要約收購期限屆滿,因需進一步確認要約收購結果,根據《上海證券交易所股票上市規則》等有關規定,經申請,公司股票於2025年7月18日(星期五)停牌一個交易日,並將在要約收購結果公告當日復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.